Onderzoeker
Gil Awada
- Trefwoorden:Geneeskunde
- Disciplines:Natuurwetenschappen, Ingenieurswetenschappen en technologie, Sociale wetenschappen
Affiliaties
- Medische Oncologie (Departement)
Lid
Vanaf1 sep 2023 → Heden - Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf22 mrt 2021 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf15 nov 2023 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf15 nov 2023 → 15 nov 2023 - Medische Oncologie (Departement)
Lid
Vanaf1 nov 2021 → 31 jul 2023 - Interne Geneeskunde (Departement)
Lid
Vanaf1 sep 2021 → 31 okt 2021 - Medische Oncologie (Departement)
Lid
Vanaf1 aug 2021 → 31 aug 2021 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf8 apr 2019 → 31 jul 2021 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 okt 2017 → 31 jul 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf13 jul 2017 → 18 jun 2021 - Interne Geneeskunde (Departement)
Lid
Vanaf1 aug 2016 → 31 jul 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf4 okt 2015 → 27 apr 2023 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf1 aug 2011 → 24 jun 2015
Publicaties
1 - 10 van 37
- Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies(2023)
Auteurs: Giuseppe Fasolino, G Awada, Laura Moschetta, Jorgos Socrates Koulalis, Bart Neyns, Bert Verhelst, Peter Van Elderen, Pieter Nelis, Paul Cardon de Lichtbuer, Wilfried Cools, et al.
- Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients(2022)
Auteurs: Julia Katharina Schwarze, Jens Tijtgat, G Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses G Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, et al.
Pagina's: 1-13 - Anti-PD-1(2022)
Auteurs: Y Jansen, Astrid A M van der Veldt, G Awada, Bart Neyns
Pagina's: 905-915 - A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors(2022)
Auteurs: G Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Vibeke Kruse, Bart Neyns
Pagina's: 183-191 - Melanoma with genetic alterations beyond the BRAFV600 mutation(2022)
Auteurs: G Awada, Bart Neyns
Pagina's: 115-122 - COVID-19 and Cushing's disease in a patient with ACTH-secreting pituitary carcinoma(2022)
Auteurs: Jeroen M.K. de Filette, Bastiaan Sol, G Awada, Corina Andreescu, David Unuane, Sandrine Aspeslagh, Jan Poelaert, Bert Bravenboer
Pagina's: 1-4 - Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial(2022)
Auteurs: Julia Katharina Schwarze, Soizic Garaud, Yanina Jansen, G Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, et al.
- Choriocapillaris Assessment In Patients Under Mek-Inhibitor Therapy For Cutaneous Melanoma(2021)
Auteurs: Giuseppe Fasolino, G Awada, Jorgos Socrates Koulalis, Bart Neyns, Peter Van Elderen, Robert Kuijpers, Pieter Nelis, Marcel Ten Tusscher
Pagina's: 765-771 - C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting(2021)
Auteurs: Justine Lauwyck, Aline Beckwée, Arno Santens, Julia Katharina Schwarze, G Awada, Valérie Vandersleyen, Sandrine Aspeslagh, Bart Neyns
Pagina's: 371-377 - Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma(2021)
Auteurs: Ine Lambert, Giuseppe Fasolino, G Awada, Robert Kuijpers, Marcel Ten Tusscher, Bart Neyns